Logo

Don Bailey

Nov 27, 2017

OncoCyte said in a document filed with the US Securities and Exchange Commission that Don Bailey has tendered his resignation from its board of directors. The firm will recruit a new independent director to fill his spot. No reason was given for his departure. Baily has been on OncoCyte's board since August. He was president and CEO of Questcor Pharmaceuticals from 2007 to 2014. From 1991 to 2000, he was CEO of Comarco, where he also served as its chairman of the board from 1998 to 2007. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.